Oncology

NICE recommends sunitinib for the first-line treatment of renal cancer

The National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending the use of sunitinib as a first-line treatment option for people with advanced and/or metastatic renal cell carcinoma who are suitable for immunotherapy and who are well enough to tolerate the treatment.
Read more

 http://www.nice.org.uk/newsevents/pressreleases/press_releas...

National Institute for Health and Clinical Excellence